Thursday, March 24, 2011

40 Years of the War on Cancer

War on Cancer is still ongoing, however, we have seen some progress which is significant, at least for those who have benefited from all these developments. A nice article (published in Science magazine) summarizes important feats that cancer researchers achieved in the last 40 years:

 (Courtesy: Science  25 March 2011: Vol. 331 no. 6024 pp. 1540-1544 )

Timeline

1971

Figure
PHOTO: LINDA BARTLETT/NCI
President Richard Nixon signs the National Cancer Act promoting the National Cancer Institute.

1973

NCI launches Surveillance Epidemiology and End Results program to collect U.S. cancer data.

1978

Figure
PHOTO: BILL BRANSON/NCI
Clinical testing begins of interferon-α, the first biological cancer therapy. FDA approves tamoxifen to prevent breast cancer recurrence.

1979

Researchers discover p53, the mutated gene most often seen in tumors.

1980

Figure
PHOTO: NCI
Robert Gallo and others isolate human T-cell lymphotropic virus-1, a cause of cancer.

1981

First cancer-prevention vaccine introduced— against human hepatitis B virus.

1983

Researchers create severe combined immunodeficient mice, a model for cancer research.

1985

Figure
PHOTO: NCI
Randomized trial shows that lumpectomy plus radiation are as effective as mastectomy for breast cancer.

1986

Biostatistician John Bailar writes in The New England Journal of Medicine, “We are losing the war against cancer.”

1989

Figure
PHOTO: PAUL SAKUMA/AP
Nobel Prize for discovering the first proto-oncogene (Src) awarded to Harold Varmus and Michael Bishop.

1991

National Breast Cancer Coalition launched, in the AIDS activist style.

1992

Figure
PHOTO: GEORGE MCGREGOR/NCI
FDA approves synthetic yew bark derivative, Taxol (paclitaxel), for breast cancer.

1993

Figure
PHOTO: SCIENCE
Congress orders study of environmental causes of breast cancer on Long Island; the 10-year study will yield no significant findings. Science names p53 “Molecule of the Year.”

1994

BRCA1 gene, identified as a risk for breast and ovarian cancer, is cloned; BRCA2 cloned the next year.

1996

American Cancer Society and others report the “first sustained decline” in overall U.S. cancer deaths, a drop of 2.6% from 1991 to 1995.

1998

FDA approves Herceptin (trastuzumab), a monoclonal antibody, for metastatic breast tumors that overproduce HER2.

1998

Figure
PHOTO: NCI
Nobelist James Watson tells The New York Times that blocking the growth of tumor blood vessels (antiangiogenesis) can “cure cancer in 2 years.”

2001

FDA approves Gleevec (imatinib), a targeted drug, for chronic myelogenous leukemia; Time calls it a “magic bullet.”

2003

Figure
PHOTO: GLOGAU PHOTOGRAPHY/NCI
NCI Director Andrew von Eschenbach vows to “eliminate suffering and death from cancer by 2015.”

2004

FDA approves Avastin, an antiangiogenesis drug, for colon cancer, with chemotherapy. Childhood cancer landmark: nearly 80% of those treated for acute lymphoblastic leukemia are free of cancer “events” for 5 years or more.

2005

Figure
CREDIT: NCI
NIH launches The Cancer Genome Atlas to catalog genomic changes in tumors.

2006

FDA approves Gardasil vaccine to prevent HPV infection, which can lead to cervical cancer.

2007–2008

Breast cancer incidence declines, attributed to better screening and reduced use of hormone replacement therapy.

2009

James Watson writes that it's time to turn from cancer genetics to “understanding the chemical reactions within cancer cells,” or cell metabolism.

2010

Figure
PHOTO: JUPITER IMAGES/THINKSTOCK
National Lung Cancer Screening Trial finds that helical CT screening can reduce cancer deaths among smokers. FDA approves Provenge, an immune treatment for metastatic prostate cancer. It extends life about 4 months and costs $93,000.

2011

PLX4032, a targeted cancer drug, extends life in patients with advanced melanoma.

No comments:

Post a Comment